Kleinman Leah, Mannix Sally, Arnold Lesley M, Burbridge Claire, Howard Kellee, McQuarrie Kelly, Pitman Verne, Resnick Malca, Roth Tom, Symonds Tara
Pfizer Ltd, Walton Oaks, Dorking Road, Walton on the Hill, Surrey KT20 7NS, Tadworth, UK.
Health Qual Life Outcomes. 2014 Jul 14;12:111. doi: 10.1186/s12955-014-0111-6.
Sleep disturbance is a common experience in fibromyalgia (FM). The field lacks a sleep specific patient reported outcome (PRO) measure developed and validated in a FM population. The study objective is to gain an in-depth understanding of sleep in FM and to develop a PRO measure of it.
Research involved the following stages: 1) A literature review conducted to identify key concepts associated with FM patient experience of sleep and PRO measures that have been used to assess this; 2) Qualitative interviews with therapeutic area experts; 3) Focus groups with FM patients who experienced sleep disturbance; 4) Development of a conceptual framework and the Fibromyalgia Sleep Diary (FMSD); and 5) Cognitive interviews with patients to explore content validity of the FMSD.
The literature review and expert interviews supported sleep disturbance being an important aspect of the FM patient experience, and underscored the need for a new FM specific sleep PRO measure. Results from the focus groups demonstrated that FM patients experience sleep disturbances that they attribute to their FM symptoms, such as pain and stiffness, confirming the importance of understanding more about sleep changes. Aspects of sleep raised by FM patients included poor sleep quality and insufficient quantity including difficulty with falling asleep, getting comfortable, and staying asleep; restlessness; light sleep; not feeling rested upon awakening; and difficulty starting the day. Cognitive interview results showed that the 8-item FMSD, developed to reflect the concepts identified above, was relevant to FM patients with content that was interpreted as intended.
The FMSD was developed in line with the recommendations of the FDA PRO guidance and ISPOR PRO Task Force. The qualitative evidence generated thus far strongly supports the content validity of the FMSD as a PRO measure of sleep disturbance in FM populations. Psychometric evaluation of the FMSD to demonstrate reliability, validity and sensitivity to change is recommended as a next step.
睡眠障碍是纤维肌痛(FM)患者的常见症状。该领域缺乏在FM人群中开发和验证的针对睡眠的患者报告结局(PRO)测量方法。本研究的目的是深入了解FM患者的睡眠情况,并开发一种针对睡眠的PRO测量方法。
研究包括以下阶段:1)进行文献综述,以确定与FM患者睡眠体验相关的关键概念以及用于评估睡眠的PRO测量方法;2)对治疗领域专家进行定性访谈;3)与经历过睡眠障碍的FM患者进行焦点小组讨论;4)开发概念框架和纤维肌痛睡眠日记(FMSD);5)对患者进行认知访谈,以探索FMSD的内容效度。
文献综述和专家访谈支持睡眠障碍是FM患者体验的一个重要方面,并强调需要一种新的针对FM的特定睡眠PRO测量方法。焦点小组讨论的结果表明,FM患者经历的睡眠障碍归因于他们的FM症状,如疼痛和僵硬,这证实了深入了解睡眠变化的重要性。FM患者提出的睡眠问题包括睡眠质量差和睡眠时间不足,如入睡困难、难以舒适入睡、难以保持睡眠状态;烦躁不安;浅睡眠;醒来后感觉没有休息好;以及难以开始新的一天。认知访谈结果表明,为反映上述概念而开发的8项FMSD与FM患者相关,其内容按预期进行了解释。
FMSD是根据美国食品药品监督管理局(FDA)PRO指南和国际药物经济学与结果研究协会(ISPOR)PRO工作组的建议开发的。迄今为止产生的定性证据有力地支持了FMSD作为FM人群睡眠障碍PRO测量方法的内容效度。建议下一步对FMSD进行心理测量评估,以证明其可靠性、有效性和对变化的敏感性。